Filtered By:
Drug: Rituxan

This page shows you your search results in order of date. This is page number 6.

Order by Relevance | Date

Total 93 results found since Jan 2013.

Update on the pharmacological treatment of adult myositis
Abstract The management of patients with idiopathic inflammatory myopathy (IIM) remains a challenge given the systemic features beyond active myositis. That is, recognizing the inflammatory arthropathy, varying dermatomyositis rashes, and overt and occult features of interstitial lung disease in addition to myositis adds to the complexity of diagnosis and treatment of IIM. However, clinicians now have available many more immunosuppressive drugs as well as biologic agents for use in patients with myositis and other autoimmune diseases. Here, the use of these agents is reviewed and support based on available published litera...
Source: Journal of Internal Medicine - April 19, 2016 Category: Internal Medicine Authors: C. V. Oddis Tags: Review Source Type: research

SRP Antibody Associated Necrotizing Myopathy Mimicked LGMD: A Case Report (P3.126)
Conclusions SRPNM can present with very slowly progressive chronic myopathy and stepwise progression. A serologic test for myositis specific antibody can lead to correct diagnosis when the clinical course and muscle biopsy findings are atypical.Disclosure: Dr. Thaisetthawatkul has nothing to disclose. Dr. McComb has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Thaisetthawatkul, P., McComb, R. Tags: Acquired Muscle Disorders: Clinical and Pathological Aspects Source Type: research

Several Atypical Presentations of TS-HDS Associated Neuropathies (P6.269)
Conclusions:It may be reasonable to consider TS-HDS associated pathology in cases of intractable pain syndromes, particularly trigeminal neuralgia, or new daily persistent headache. Cranial nerve lesions other than pain, such as diplopia may be associated with TS-HDS versus IgM antibody pathology. Immune modulation, such as plasmapheresis or rituximab, may be an intervention to treat cases such as those presented which were previously thought intractable.Disclosure: Dr. Lucchese has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Lucchese, S. Tags: Pain and Palliative Care Source Type: research

Management of connective tissue diseases associated interstitial lung disease: a review of the published literature
Purpose of review: Interstitial lung disease (ILD), though a common and often a severe manifestation of many connective tissue diseases (CTD), is challenging to manage because of its variable presentation and the relative lack of guidelines to assist the clinician. In this review, we discuss the approach to diagnosis, treatment, and monitoring patients with CTD-associated ILD, with a focus on systemic sclerosis (SSc), rheumatoid arthritis (RA), and idiopathic inflammatory myopathy (IIM). Recent findings: High-resolution computed tomography scan and pulmonary function testing can be reliably used to diagnose ILD and monito...
Source: Current Opinion in Rheumatology - April 1, 2016 Category: Rheumatology Tags: CLINICAL THERAPEUTICS: Edited by W. Joseph McCune Source Type: research

Treatment of inflammatory myopathy: emerging therapies and therapeutic targets.
Authors: Moghadam-Kia S, Aggarwal R, Oddis CV Abstract Despite the lack of placebo-controlled trials, glucocorticoids are considered the mainstay of initial treatment for idiopathic inflammatory myopathy and myositis-associated interstitial lung disease. Glucocorticoid-sparing agents are often given concomitantly with other immunosuppressive agents, particularly in patients with moderate or severe disease. First-line conventional immunosuppressive drugs include either methotrexate or azathioprine, and when they fail, more aggressive therapy includes mycophenolate mofetil, tacrolimus or cyclosporine, intravenous imm...
Source: Expert Review of Clinical Immunology - February 17, 2016 Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research

Magnetic resonance measurement of muscle T2, fat-corrected T2 and fat fraction in the assessment of idiopathic inflammatory myopathies
Conclusion. Muscle T2, fc-T2 and FF measurements exhibit content validity with reference to semi-quantitative scoring of STIR and T1 MRI, and also exhibit construct validity with reference to several myositis activity and damage measures. T2 was as responsive as fc-T2 and STIR scoring, although progression of muscle damage was negligible during the study.
Source: Rheumatology - February 8, 2016 Category: Rheumatology Authors: Yao, L., Yip, A. L., Shrader, J. A., Mesdaghinia, S., Volochayev, R., Jansen, A. V., Miller, F. W., Rider, L. G. Tags: Myositis and Muscle Disease, Diagnostics and Imaging Procedures CLINICAL SCIENCE Source Type: research

Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics
Abstract Despite the lack of placebo-controlled trials, glucocorticoids are considered the mainstay of initial treatment for idiopathic inflammatory myopathy (IIMs) and myositis-associated ILD (MA-ILD). Glucocorticoid-sparing agents are often given concomitantly with other immunosuppressive agents, particularly in patients with moderate or severe disease. As treatment of refractory cases of idiopathic inflammatory myopathies has been challenging, there is growing interest in evaluating newer therapies including biologics that target various pathways involved in the pathogenesis of IIMs. In a large clinical trial o...
Source: Clinical Reviews in Allergy and Immunology - January 14, 2016 Category: Allergy & Immunology Source Type: research

Interstitial lung disease with statin-associated necrotizing autoimmune myopathy responding to rituximab.
PMID: 26744248 [PubMed - as supplied by publisher]
Source: Archivos de Bronconeumologia - December 29, 2015 Category: Respiratory Medicine Authors: Meira Dias O, Guedes Baldi B, Nathan Costa A, Katsuyuki Shinjo S, Miossi R, Adib Kairalla R Tags: Arch Bronconeumol Source Type: research

Interferon-regulated chemokine score associated with improvement in disease activity in refractory myositis patients treated with rituximab.
CONCLUSIONS: IFN-regulated chemokines before treatment is associated with improvement in disease activity measures in refractory myositis patients treated with rituximab. PMID: 26446265 [PubMed - in process]
Source: Clinical and Experimental Rheumatology - October 10, 2015 Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research

Sonographic monitoring of severe focal B‐cell myositis of the anterior calf muscle responsive to rituximab
Conclusions: This case report further strengthens the underlying autoimmune pathogenesis of focal myositis. In addition it shows that B‐cell directed therapies in individual corticosteroid non‐responding cases may be efficient especially when muscle biopsy shows significant B‐cell infiltration. Furthermore, it also underlines the value of myosonography in the monitoring of focal myositis. This article is protected by copyright. All rights reserved.
Source: Muscle and Nerve - June 25, 2015 Category: Internal Medicine Authors: Christiane Schneider‐Gold, Christos Krogias, Clemens Neusch, Martin Hasselblatt, Ralf Gold Tags: Letter to the Editor Source Type: research

Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy
Conclusions: Recognition of HMGCR antibody–associated NAM is important because these patients are responsive to immunosuppression, and early multiagent therapy and a slow and cautious approach to withdrawing steroids may improve outcomes.
Source: Neurology Neuroimmunology and Neuroinflammation - April 2, 2015 Category: Neurology Authors: Ramanathan, S., Langguth, D., Hardy, T. A., Garg, N., Bundell, C., Rojana-Udomsart, A., Dale, R. C., Robertson, T., Mammen, A. L., Reddel, S. W. Tags: Article Source Type: research

Quickly progressive amyotrophy of the thigh: An unusual cause of rapid chondrolysis of the knee
Publication date: Available online 10 February 2015 Source:Joint Bone Spine Author(s): Maeva Ferrari , Karine Louati , Anne Miquel , Anthony Behin , Olivier Benveniste , Jérémie Sellam While rapidly destructive OA is more recognized in hip, we report the case of a 50-year-old woman who presented a rapid chondrolysis in the patellofemoral joint in a context of rapid loss of muscular strength. She had arthralgia, myalgia and proximal muscular deficit of the limbs. Creatine phospho kinase level was elevated and electromyogram exam showed a myogenic syndrome. Neither immune nor visceral disease was highlighted. As we suspe...
Source: Joint Bone Spine - February 13, 2015 Category: Orthopaedics Source Type: research

Acute treatment-resistant post-partum necrotising myopathy with anti-Ro52/TRIM21 antibodies treated with rituximab
Source: Rheumatology International - January 8, 2015 Category: Rheumatology Source Type: research

G.P.74: Anti-Signal Recognition Particle associated myopathy in a multiethnic Malaysian population
We describe a series of Malaysian patients with anti-SRP myopathy. Of 30 patients with idiopathic inflammatory myopathy, seen prospectively at the University of Malaya Medical Centre, Kuala Lumpur between 2012 and 2014, eight (26.7%) had positive anti-SRP antibodies. All patients were female, of whom four were ethnic Malays and four, ethnic Chinese. Their mean age of disease onset was 37years (range 24–60years). All presented with progressive severe proximal muscle weakness. Mean serum creatine kinase at presentation was 4994u/L (range 385–14,000iu/L). Muscle histopathology showed muscle fibre necrosis with variable re...
Source: Neuromuscular Disorders - September 4, 2014 Category: Neurology Authors: T. Ambang, J.S. Tan, T.E. Cheah, N. Shahrizaila, K.T. Wong, K.J. Goh Source Type: research

CNS Toxoplasmosis: A Serious Complication Of Immunotherapy In The Neuromuscular Patient (P6.102)
Conclusions: Immunotherapy with medication such as MM can cause a devastating CNS toxoplasmosis in non-HIV patients with neuromuscular disorders. In contrast to the HIV infected patients, treatment is ineffective implying a different pathogenesis. Early consideration and recognition of this complication is important to possibly prevent unfavorable outcome.Disclosure: Dr. Bernardo has nothing to disclose. Dr. Chahin has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Bernardo, D., Chahin, N. Tags: Neuromuscular Disease Source Type: research